Long-Term Kinetics of SARS-CoV-2 Neutralizing and Anti-Receptor Binding Domain Antibodies among Laboratory-Confirmed COVID-19 Cases in Delhi National Capital Region, India: A Prospective, One-Year Follow-Up Study
This study was conducted with the objective of measuring the neutralizing and anti-receptor binding domain antibody levels against SARS-CoV-2 among laboratory-confirmed COVID-19 cases and exploring its long-term kinetics over a period of 1 year. One hundred laboratory-confirmed COVID-19 cases were r...
Gespeichert in:
| Veröffentlicht in: | Journal of clinical medicine 2024-01, Vol.13 (3), p.762 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 3 |
| container_start_page | 762 |
| container_title | Journal of clinical medicine |
| container_volume | 13 |
| creator | Misra, Puneet Medigeshi, Guruprasad R Kant, Shashi Jaiswal, Abhishek Ahmad, Mohammad Rahman, Anisur Guleria, Randeep Rai, Sanjay Kumar Deori, Trideep Jyoti Mandal, Suprakash Gongal, Gaurav Bairwa, Mohan Haldar, Partha Kumar, Rakesh Garg, Neha |
| description | This study was conducted with the objective of measuring the neutralizing and anti-receptor binding domain antibody levels against SARS-CoV-2 among laboratory-confirmed COVID-19 cases and exploring its long-term kinetics over a period of 1 year.
One hundred laboratory-confirmed COVID-19 cases were recruited. Serum samples of the participants were collected within three months from the date of the positive COVID-19 report. The participants were prospectively followed up every three months for symptoms and the collection of blood samples for three additional rounds. The presence of anti-SARS-CoV-2 antibodies (IgA, IgG, and IgM antibodies), anti-receptor binding domain antibodies (anti-RBD), and neutralizing antibodies were measured.
Median plaque reduction neutralization test (PRNT) titers showed a rising trend in the first three rounds of follow-up. The quantitative anti-receptor binding domain ELISA (QRBD) values showed a declining trend in the initial three rounds. However, both the PRNT titers and QRBD values showed significantly higher values for the fourth round of follow-up. Total antibody (WANTAI) levels showed an increasing trend in the initial three rounds (statistically significant).
Neutralizing antibodies showed an increasing trend. The anti-receptor binding domain antibodies showed a decreasing trend. Neutralizing antibodies and anti-RBD antibodies persisted in the majority. |
| doi_str_mv | 10.3390/jcm13030762 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_2925034710</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A782091216</galeid><sourcerecordid>A782091216</sourcerecordid><originalsourceid>FETCH-LOGICAL-c379t-870d9718ea501eaa625a7690561f40b57102c0ef588a85d88d8176648c1518613</originalsourceid><addsrcrecordid>eNptklFv0zAQxyMEYtPYE-_IEi9IzMOOk9jhrbQMKqoNtdskniLXuRRXiR3sBFQ-Jx-I6zZgIOyHs_7-3d_2-ZLkKWenQpTs1dZ0XDDBZJE-SA5TJiVlQomH99YHyXGMW4ZDqSzl8nFygKqQWS4Pkx8L7zb0EkJHPlgHgzWR-IasJssVnfprmpJzGIegW_vdug3RriYTN1i6BAP94AN5Y12935n5Tlt3s7n2tYVIdIfWZKHXPmgkd-jnGhs6qMn04no-o7wkUx2RxLwZtJ8tOdeD9U63qPd2wLiEDQonZI6H6NdkQj4GH3swg_0KJ-TCAf0EOpAz37b-G73qyWoY692T5FGj2wjHd_EouTp7ezl9TxcX7-bTyYIaIcuBKsnqUnIFOmcctC7SXMuiZHnBm4ytc8lZahg0uVJa5bVSteKyKDJleM5VwcVR8uLWtw_-ywhxqDobDbStduDHWKVlmjORoQ-iz_9Bt34M-NQbSpSZypn6Q210C5V1jcfSm71pNZEqZSVPeYHU6X8onDV01ngHjUX9r4SXtwkGqxcDNFUfbKfDruKs2rdRda-NkH52d9VxjZ_1m_3VNOInu3O-3g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2923948508</pqid></control><display><type>article</type><title>Long-Term Kinetics of SARS-CoV-2 Neutralizing and Anti-Receptor Binding Domain Antibodies among Laboratory-Confirmed COVID-19 Cases in Delhi National Capital Region, India: A Prospective, One-Year Follow-Up Study</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central Open Access</source><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>PubMed Central</source><creator>Misra, Puneet ; Medigeshi, Guruprasad R ; Kant, Shashi ; Jaiswal, Abhishek ; Ahmad, Mohammad ; Rahman, Anisur ; Guleria, Randeep ; Rai, Sanjay Kumar ; Deori, Trideep Jyoti ; Mandal, Suprakash ; Gongal, Gaurav ; Bairwa, Mohan ; Haldar, Partha ; Kumar, Rakesh ; Garg, Neha</creator><creatorcontrib>Misra, Puneet ; Medigeshi, Guruprasad R ; Kant, Shashi ; Jaiswal, Abhishek ; Ahmad, Mohammad ; Rahman, Anisur ; Guleria, Randeep ; Rai, Sanjay Kumar ; Deori, Trideep Jyoti ; Mandal, Suprakash ; Gongal, Gaurav ; Bairwa, Mohan ; Haldar, Partha ; Kumar, Rakesh ; Garg, Neha</creatorcontrib><description>This study was conducted with the objective of measuring the neutralizing and anti-receptor binding domain antibody levels against SARS-CoV-2 among laboratory-confirmed COVID-19 cases and exploring its long-term kinetics over a period of 1 year.
One hundred laboratory-confirmed COVID-19 cases were recruited. Serum samples of the participants were collected within three months from the date of the positive COVID-19 report. The participants were prospectively followed up every three months for symptoms and the collection of blood samples for three additional rounds. The presence of anti-SARS-CoV-2 antibodies (IgA, IgG, and IgM antibodies), anti-receptor binding domain antibodies (anti-RBD), and neutralizing antibodies were measured.
Median plaque reduction neutralization test (PRNT) titers showed a rising trend in the first three rounds of follow-up. The quantitative anti-receptor binding domain ELISA (QRBD) values showed a declining trend in the initial three rounds. However, both the PRNT titers and QRBD values showed significantly higher values for the fourth round of follow-up. Total antibody (WANTAI) levels showed an increasing trend in the initial three rounds (statistically significant).
Neutralizing antibodies showed an increasing trend. The anti-receptor binding domain antibodies showed a decreasing trend. Neutralizing antibodies and anti-RBD antibodies persisted in the majority.</description><identifier>ISSN: 2077-0383</identifier><identifier>EISSN: 2077-0383</identifier><identifier>DOI: 10.3390/jcm13030762</identifier><identifier>PMID: 38337457</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Antibodies ; Asymptomatic ; COVID-19 vaccines ; Data collection ; Enzymes ; Fever ; Forecasts and trends ; Identification and classification ; Immunoassay ; Infections ; Laboratories ; Proteins ; Serology ; Severe acute respiratory syndrome coronavirus 2 ; Testing ; Viral antibodies</subject><ispartof>Journal of clinical medicine, 2024-01, Vol.13 (3), p.762</ispartof><rights>COPYRIGHT 2024 MDPI AG</rights><rights>2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c379t-870d9718ea501eaa625a7690561f40b57102c0ef588a85d88d8176648c1518613</cites><orcidid>0000-0002-2019-1524 ; 0000-0001-5333-9743 ; 0000-0002-1289-5425 ; 0000-0001-7763-2530</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38337457$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Misra, Puneet</creatorcontrib><creatorcontrib>Medigeshi, Guruprasad R</creatorcontrib><creatorcontrib>Kant, Shashi</creatorcontrib><creatorcontrib>Jaiswal, Abhishek</creatorcontrib><creatorcontrib>Ahmad, Mohammad</creatorcontrib><creatorcontrib>Rahman, Anisur</creatorcontrib><creatorcontrib>Guleria, Randeep</creatorcontrib><creatorcontrib>Rai, Sanjay Kumar</creatorcontrib><creatorcontrib>Deori, Trideep Jyoti</creatorcontrib><creatorcontrib>Mandal, Suprakash</creatorcontrib><creatorcontrib>Gongal, Gaurav</creatorcontrib><creatorcontrib>Bairwa, Mohan</creatorcontrib><creatorcontrib>Haldar, Partha</creatorcontrib><creatorcontrib>Kumar, Rakesh</creatorcontrib><creatorcontrib>Garg, Neha</creatorcontrib><title>Long-Term Kinetics of SARS-CoV-2 Neutralizing and Anti-Receptor Binding Domain Antibodies among Laboratory-Confirmed COVID-19 Cases in Delhi National Capital Region, India: A Prospective, One-Year Follow-Up Study</title><title>Journal of clinical medicine</title><addtitle>J Clin Med</addtitle><description>This study was conducted with the objective of measuring the neutralizing and anti-receptor binding domain antibody levels against SARS-CoV-2 among laboratory-confirmed COVID-19 cases and exploring its long-term kinetics over a period of 1 year.
One hundred laboratory-confirmed COVID-19 cases were recruited. Serum samples of the participants were collected within three months from the date of the positive COVID-19 report. The participants were prospectively followed up every three months for symptoms and the collection of blood samples for three additional rounds. The presence of anti-SARS-CoV-2 antibodies (IgA, IgG, and IgM antibodies), anti-receptor binding domain antibodies (anti-RBD), and neutralizing antibodies were measured.
Median plaque reduction neutralization test (PRNT) titers showed a rising trend in the first three rounds of follow-up. The quantitative anti-receptor binding domain ELISA (QRBD) values showed a declining trend in the initial three rounds. However, both the PRNT titers and QRBD values showed significantly higher values for the fourth round of follow-up. Total antibody (WANTAI) levels showed an increasing trend in the initial three rounds (statistically significant).
Neutralizing antibodies showed an increasing trend. The anti-receptor binding domain antibodies showed a decreasing trend. Neutralizing antibodies and anti-RBD antibodies persisted in the majority.</description><subject>Antibodies</subject><subject>Asymptomatic</subject><subject>COVID-19 vaccines</subject><subject>Data collection</subject><subject>Enzymes</subject><subject>Fever</subject><subject>Forecasts and trends</subject><subject>Identification and classification</subject><subject>Immunoassay</subject><subject>Infections</subject><subject>Laboratories</subject><subject>Proteins</subject><subject>Serology</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Testing</subject><subject>Viral antibodies</subject><issn>2077-0383</issn><issn>2077-0383</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNptklFv0zAQxyMEYtPYE-_IEi9IzMOOk9jhrbQMKqoNtdskniLXuRRXiR3sBFQ-Jx-I6zZgIOyHs_7-3d_2-ZLkKWenQpTs1dZ0XDDBZJE-SA5TJiVlQomH99YHyXGMW4ZDqSzl8nFygKqQWS4Pkx8L7zb0EkJHPlgHgzWR-IasJssVnfprmpJzGIegW_vdug3RriYTN1i6BAP94AN5Y12935n5Tlt3s7n2tYVIdIfWZKHXPmgkd-jnGhs6qMn04no-o7wkUx2RxLwZtJ8tOdeD9U63qPd2wLiEDQonZI6H6NdkQj4GH3swg_0KJ-TCAf0EOpAz37b-G73qyWoY692T5FGj2wjHd_EouTp7ezl9TxcX7-bTyYIaIcuBKsnqUnIFOmcctC7SXMuiZHnBm4ytc8lZahg0uVJa5bVSteKyKDJleM5VwcVR8uLWtw_-ywhxqDobDbStduDHWKVlmjORoQ-iz_9Bt34M-NQbSpSZypn6Q210C5V1jcfSm71pNZEqZSVPeYHU6X8onDV01ngHjUX9r4SXtwkGqxcDNFUfbKfDruKs2rdRda-NkH52d9VxjZ_1m_3VNOInu3O-3g</recordid><startdate>20240129</startdate><enddate>20240129</enddate><creator>Misra, Puneet</creator><creator>Medigeshi, Guruprasad R</creator><creator>Kant, Shashi</creator><creator>Jaiswal, Abhishek</creator><creator>Ahmad, Mohammad</creator><creator>Rahman, Anisur</creator><creator>Guleria, Randeep</creator><creator>Rai, Sanjay Kumar</creator><creator>Deori, Trideep Jyoti</creator><creator>Mandal, Suprakash</creator><creator>Gongal, Gaurav</creator><creator>Bairwa, Mohan</creator><creator>Haldar, Partha</creator><creator>Kumar, Rakesh</creator><creator>Garg, Neha</creator><general>MDPI AG</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-2019-1524</orcidid><orcidid>https://orcid.org/0000-0001-5333-9743</orcidid><orcidid>https://orcid.org/0000-0002-1289-5425</orcidid><orcidid>https://orcid.org/0000-0001-7763-2530</orcidid></search><sort><creationdate>20240129</creationdate><title>Long-Term Kinetics of SARS-CoV-2 Neutralizing and Anti-Receptor Binding Domain Antibodies among Laboratory-Confirmed COVID-19 Cases in Delhi National Capital Region, India: A Prospective, One-Year Follow-Up Study</title><author>Misra, Puneet ; Medigeshi, Guruprasad R ; Kant, Shashi ; Jaiswal, Abhishek ; Ahmad, Mohammad ; Rahman, Anisur ; Guleria, Randeep ; Rai, Sanjay Kumar ; Deori, Trideep Jyoti ; Mandal, Suprakash ; Gongal, Gaurav ; Bairwa, Mohan ; Haldar, Partha ; Kumar, Rakesh ; Garg, Neha</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c379t-870d9718ea501eaa625a7690561f40b57102c0ef588a85d88d8176648c1518613</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Antibodies</topic><topic>Asymptomatic</topic><topic>COVID-19 vaccines</topic><topic>Data collection</topic><topic>Enzymes</topic><topic>Fever</topic><topic>Forecasts and trends</topic><topic>Identification and classification</topic><topic>Immunoassay</topic><topic>Infections</topic><topic>Laboratories</topic><topic>Proteins</topic><topic>Serology</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Testing</topic><topic>Viral antibodies</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Misra, Puneet</creatorcontrib><creatorcontrib>Medigeshi, Guruprasad R</creatorcontrib><creatorcontrib>Kant, Shashi</creatorcontrib><creatorcontrib>Jaiswal, Abhishek</creatorcontrib><creatorcontrib>Ahmad, Mohammad</creatorcontrib><creatorcontrib>Rahman, Anisur</creatorcontrib><creatorcontrib>Guleria, Randeep</creatorcontrib><creatorcontrib>Rai, Sanjay Kumar</creatorcontrib><creatorcontrib>Deori, Trideep Jyoti</creatorcontrib><creatorcontrib>Mandal, Suprakash</creatorcontrib><creatorcontrib>Gongal, Gaurav</creatorcontrib><creatorcontrib>Bairwa, Mohan</creatorcontrib><creatorcontrib>Haldar, Partha</creatorcontrib><creatorcontrib>Kumar, Rakesh</creatorcontrib><creatorcontrib>Garg, Neha</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of clinical medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Misra, Puneet</au><au>Medigeshi, Guruprasad R</au><au>Kant, Shashi</au><au>Jaiswal, Abhishek</au><au>Ahmad, Mohammad</au><au>Rahman, Anisur</au><au>Guleria, Randeep</au><au>Rai, Sanjay Kumar</au><au>Deori, Trideep Jyoti</au><au>Mandal, Suprakash</au><au>Gongal, Gaurav</au><au>Bairwa, Mohan</au><au>Haldar, Partha</au><au>Kumar, Rakesh</au><au>Garg, Neha</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Long-Term Kinetics of SARS-CoV-2 Neutralizing and Anti-Receptor Binding Domain Antibodies among Laboratory-Confirmed COVID-19 Cases in Delhi National Capital Region, India: A Prospective, One-Year Follow-Up Study</atitle><jtitle>Journal of clinical medicine</jtitle><addtitle>J Clin Med</addtitle><date>2024-01-29</date><risdate>2024</risdate><volume>13</volume><issue>3</issue><spage>762</spage><pages>762-</pages><issn>2077-0383</issn><eissn>2077-0383</eissn><abstract>This study was conducted with the objective of measuring the neutralizing and anti-receptor binding domain antibody levels against SARS-CoV-2 among laboratory-confirmed COVID-19 cases and exploring its long-term kinetics over a period of 1 year.
One hundred laboratory-confirmed COVID-19 cases were recruited. Serum samples of the participants were collected within three months from the date of the positive COVID-19 report. The participants were prospectively followed up every three months for symptoms and the collection of blood samples for three additional rounds. The presence of anti-SARS-CoV-2 antibodies (IgA, IgG, and IgM antibodies), anti-receptor binding domain antibodies (anti-RBD), and neutralizing antibodies were measured.
Median plaque reduction neutralization test (PRNT) titers showed a rising trend in the first three rounds of follow-up. The quantitative anti-receptor binding domain ELISA (QRBD) values showed a declining trend in the initial three rounds. However, both the PRNT titers and QRBD values showed significantly higher values for the fourth round of follow-up. Total antibody (WANTAI) levels showed an increasing trend in the initial three rounds (statistically significant).
Neutralizing antibodies showed an increasing trend. The anti-receptor binding domain antibodies showed a decreasing trend. Neutralizing antibodies and anti-RBD antibodies persisted in the majority.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>38337457</pmid><doi>10.3390/jcm13030762</doi><orcidid>https://orcid.org/0000-0002-2019-1524</orcidid><orcidid>https://orcid.org/0000-0001-5333-9743</orcidid><orcidid>https://orcid.org/0000-0002-1289-5425</orcidid><orcidid>https://orcid.org/0000-0001-7763-2530</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2077-0383 |
| ispartof | Journal of clinical medicine, 2024-01, Vol.13 (3), p.762 |
| issn | 2077-0383 2077-0383 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2925034710 |
| source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central Open Access; MDPI - Multidisciplinary Digital Publishing Institute; PubMed Central |
| subjects | Antibodies Asymptomatic COVID-19 vaccines Data collection Enzymes Fever Forecasts and trends Identification and classification Immunoassay Infections Laboratories Proteins Serology Severe acute respiratory syndrome coronavirus 2 Testing Viral antibodies |
| title | Long-Term Kinetics of SARS-CoV-2 Neutralizing and Anti-Receptor Binding Domain Antibodies among Laboratory-Confirmed COVID-19 Cases in Delhi National Capital Region, India: A Prospective, One-Year Follow-Up Study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T07%3A56%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Long-Term%20Kinetics%20of%20SARS-CoV-2%20Neutralizing%20and%20Anti-Receptor%20Binding%20Domain%20Antibodies%20among%20Laboratory-Confirmed%20COVID-19%20Cases%20in%20Delhi%20National%20Capital%20Region,%20India:%20A%20Prospective,%20One-Year%20Follow-Up%20Study&rft.jtitle=Journal%20of%20clinical%20medicine&rft.au=Misra,%20Puneet&rft.date=2024-01-29&rft.volume=13&rft.issue=3&rft.spage=762&rft.pages=762-&rft.issn=2077-0383&rft.eissn=2077-0383&rft_id=info:doi/10.3390/jcm13030762&rft_dat=%3Cgale_proqu%3EA782091216%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2923948508&rft_id=info:pmid/38337457&rft_galeid=A782091216&rfr_iscdi=true |